NO20063564L - Helix 12 rettede sterodiale farmasoytiske produkter - Google Patents

Helix 12 rettede sterodiale farmasoytiske produkter

Info

Publication number
NO20063564L
NO20063564L NO20063564A NO20063564A NO20063564L NO 20063564 L NO20063564 L NO 20063564L NO 20063564 A NO20063564 A NO 20063564A NO 20063564 A NO20063564 A NO 20063564A NO 20063564 L NO20063564 L NO 20063564L
Authority
NO
Norway
Prior art keywords
treat
tissue
sterodial
helix
targeted
Prior art date
Application number
NO20063564A
Other languages
English (en)
Norwegian (no)
Inventor
Shankar Singh
Sylvain Gauthier
Fernand Labrie
Yvon Frechette
Sylvain Chenard
Rock Breton
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of NO20063564L publication Critical patent/NO20063564L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20063564A 2004-01-07 2006-08-07 Helix 12 rettede sterodiale farmasoytiske produkter NO20063564L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53512104P 2004-01-07 2004-01-07
PCT/CA2005/000011 WO2005066194A1 (en) 2004-01-07 2005-01-06 Helix 12 directed steroidal pharmaceutical products

Publications (1)

Publication Number Publication Date
NO20063564L true NO20063564L (no) 2006-10-09

Family

ID=34749018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063564A NO20063564L (no) 2004-01-07 2006-08-07 Helix 12 rettede sterodiale farmasoytiske produkter

Country Status (16)

Country Link
US (1) US9090651B2 (ja)
EP (1) EP1704161A4 (ja)
JP (1) JP4866740B2 (ja)
KR (2) KR20130124576A (ja)
CN (2) CN1930181A (ja)
AU (2) AU2005203922A1 (ja)
BR (1) BRPI0506470A (ja)
CA (1) CA2551737C (ja)
HK (1) HK1167657A1 (ja)
IL (1) IL176538A0 (ja)
MY (1) MY157898A (ja)
NO (1) NO20063564L (ja)
RU (1) RU2397176C2 (ja)
TW (1) TWI383993B (ja)
WO (1) WO2005066194A1 (ja)
ZA (1) ZA200605242B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
NZ554619A (en) 2004-10-20 2011-01-28 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
GB0428128D0 (en) * 2004-12-22 2005-01-26 Avecia Ltd Process
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
WO2009105214A2 (en) * 2008-02-22 2009-08-27 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
GB2461037A (en) * 2008-06-17 2009-12-23 Elias Bouras A method of treating alopecia using a composition comprising a cardiac glycoside
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
EP2576514A1 (en) 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
JP5965909B2 (ja) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
CN102746360B (zh) * 2012-06-19 2014-07-02 广西民族大学 四种喜树碱-甾体缀合物的合成及其应用
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN105237605B (zh) * 2014-07-11 2019-01-25 上海迪赛诺生物医药有限公司 一种用于合成孕二烯酮的中间体及其制备方法和应用
CN105237606B (zh) * 2014-07-11 2018-08-24 上海创诺制药有限公司 一种用于合成去氧孕烯的中间体及其制备方法和应用
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
KR102397890B1 (ko) 2016-06-22 2022-05-12 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
CN108822175B (zh) * 2018-04-26 2021-01-05 昆明理工大学 3,16-雄甾烯二酮类化合物及其应用
AU2019297421A1 (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
DE3761308D1 (de) * 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
WO1995018821A2 (en) 1994-01-06 1995-07-13 Sri International Novel antiandrogenic agents and related pharmaceutical compositions and methods of use
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
CN1429104A (zh) 1998-03-11 2003-07-09 内部研究股份有限公司 5型和3型17β－羟基类固醇脱氢酶的抑制剂及其用法
JP2004509072A (ja) 2000-06-28 2004-03-25 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
EP1304334A4 (en) 2000-06-30 2009-06-17 Chugai Pharmaceutical Co Ltd NEW ANTIANDROGEN AGENT
WO2003022835A1 (en) 2001-09-06 2003-03-20 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP1474127B1 (en) * 2002-02-15 2006-11-15 Endorecherche, Inc. Biphenyl derivatives and their use as antiandrogenic agents
IL163825A0 (en) * 2002-03-13 2005-12-18 Merck & Co Inc Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AU2003223754B2 (en) * 2002-04-30 2007-08-16 Merck Sharp & Dohme Corp. 4-azasteroid derivatives as androgen receptor modulators
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Also Published As

Publication number Publication date
JP4866740B2 (ja) 2012-02-01
KR101536701B1 (ko) 2015-07-14
AU2009202038A1 (en) 2009-06-11
HK1167657A1 (zh) 2012-12-07
AU2005203922A1 (en) 2005-07-21
KR20130124576A (ko) 2013-11-14
MY157898A (en) 2016-08-15
JP2007519635A (ja) 2007-07-19
TW200530264A (en) 2005-09-16
WO2005066194A1 (en) 2005-07-21
CN1930181A (zh) 2007-03-14
BRPI0506470A (pt) 2007-02-21
EP1704161A4 (en) 2011-06-08
EP1704161A1 (en) 2006-09-27
CN102358750B (zh) 2015-11-25
IL176538A0 (en) 2006-10-05
CA2551737C (en) 2009-11-10
TWI383993B (zh) 2013-02-01
CA2551737A1 (en) 2005-07-21
US20050250749A1 (en) 2005-11-10
US9090651B2 (en) 2015-07-28
AU2009202038A2 (en) 2009-08-06
RU2397176C2 (ru) 2010-08-20
RU2006128574A (ru) 2008-02-20
CN102358750A (zh) 2012-02-22
KR20070003851A (ko) 2007-01-05
ZA200605242B (en) 2007-10-31

Similar Documents

Publication Publication Date Title
NO20063564L (no) Helix 12 rettede sterodiale farmasoytiske produkter
NO20080143L (no) Helix 12 directed non-steroidal antiandrogens
DK1494993T3 (da) Hidtil ukendte Curcumin-analoger og anvendelser deraf
DE60309667D1 (de) Biphenylderivate und ihre verwendung als antiandrogene
WO2006044379A3 (en) Novel curcumin analogues and uses thereof
TW270922B (ja)
WO2006040688B1 (en) Inhibitors of acetylcholinesterase for treating skin diseases
NO308037B1 (no) 16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat
DK0724444T3 (da) Fremgangsmåde til behandling af androgen alopecia med inhibitorer for 5-alfa-reduktase
NO20053649D0 (no) Kombinasjonsterapi
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
AR021757A1 (es) Metodo para inhibir la conversion de 4-androstan-3,17-diona en testosterona o de 3alfa-androstan-3,17-diona en dihidrotestosterona, inhibir la actividadde la 3alfa-hidroxiesteroide deshidrogenasa de tipo 3 humana, para determinar la eficacia de un inhibidor putativo de la conversion de 4-androsten-3
EA201691267A1 (ru) Нестероидные антиандрогены и селективные модуляторы андрогеновых рецепторов с пиридильной группой
MXPA03002495A (es) Proceso para preparacion de compuestos de n-(fenil sustituido)-3-alquil, aril- y heteroarilsulfonil-2-hidroxi-2-alquil- y haloalquilpropanamida.
WO2008013791A3 (en) Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
DE69417925T2 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
WO2005079164A3 (ja) ５α−リダクターゼ阻害剤
WO2005079164A1 (ja) ５α−リダクターゼ阻害剤
UA97786C2 (ru) Нестероидные антиандрогены, направленные на 12-спираль рецептора антиандрогенов
WO2010143803A3 (en) New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same
DE60104589D1 (de) Therapeutisches Mittel zur Behandlung von Dermatitis
Byrne Importance of the tumour microenvironment in the treatment response of prostate tumours
Bhattacharya Comparison of Different Lattice Models of Amphiphiles: A Monte Carlo Study.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO

FC2A Withdrawal, rejection or dismissal of laid open patent application